Kv11.1 Channel Blocker Reverses Pulmonary Hypertension Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary artery hypertension (PAH) are limited and lack effective therapeutic options, with little known about the role of Kv11.1 channels in pulmonary vasculature and their potential in vascular remodeling associated with PAH and chronic obstructive pulmonary disease (COPD).
Innovation Solution
Kv11.1 channel expression was found in healthy and PAH-affected lungs, with the Kv11.1 channel blocker dofetilide reducing PAH-associated vascular remodeling by increasing arterial lumen opening and decreasing arterial wall thickness, suggesting Kv11.1 channels as novel drug targets for PAH treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for PAH are used, then symptoms can be relieved, but there is no known cure and treatment options are limited
Solution Approach 1:
The patent identifies Kv11.1 channels as a novel therapeutic target for PAH treatment. By changing the parameter of drug target selection from conventional targets to Kv11.1 channels, the invention provides new treatment options and improves therapeutic efficacy. The discovery that Kv11.1 channels are upregulated in PAH-affected lungs and that blocking them reverses vascular remodeling offers a fundamentally new approach to treating this currently incurable disease.
2Reliability
If Kv11.1 channel expression is increased in PAH-affected lungs, then vascular remodeling occurs, but blocking Kv11.1 channels reverses the remodeling
Solution Approach 1:
The patent converts the harmful effect of Kv11.1 channel upregulation (which causes vascular remodeling and PAH progression) into a beneficial therapeutic opportunity. By identifying Kv11.1 channels as the cause of harmful vascular remodeling, the invention enables targeted blockade of these channels to reverse the remodeling process. This transforms the previously harmful upregulation into a treatable condition, converting the disease mechanism itself into a therapeutic target.
3Reliability
If dofetilide is administered to PAH-induced rats, then arterial lumen opening increases and arterial wall thickness decreases, but cardiac arrhythmia risk may occur
Solution Approach 1:
The patent applies the principle of local quality by focusing the therapeutic effect of Kv11.1 channel blockade specifically on pulmonary vasculature rather than systemically. The invention seeks to achieve selective blockade in lung arteries where Kv11.1 channels are upregulated, while minimizing effects on cardiac tissue. This localized approach allows reversal of pulmonary vascular remodeling without causing the cardiac arrhythmias that would result from systemic Kv11.1 channel blockade.
Data Source
AI summary
Provided are methods of treating pulmonary artery hypertension with a Kv11.1 (ERG or hERG1) channel inhibitor. In certain embodiments, the Kv11.1 channel inhibitor is dofetilide. In certain embodiments, a subject to be treated using a method of the disclosure is not in need of treatment for an irregular heart rhythm, e.g., atrial fibrillation.